Logo Medical Science Monitor Basic Research

Call: 1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Contact Us

Logo Medical Science Monitor Basic Research Logo Medical Science Monitor Basic Research Logo Medical Science Monitor Basic Research

02 January 2022: Clinical Research

Retrospective Study of 573 Patients with Heart Failure Evaluated for Coronary Artery Disease at Toulouse University Center, France

Antoine Deney 1ABCDEF* , Vanessa Nader 12ABCDEF* , Anthony Matta 13ABCDE , Romain Itier 1CDE , Pauline Fournier 1ABCD , Olivier Lairez 1ADF , Nathalie Pizzinat 4ACD , Didier Carrié 1ACD , Frédéric Boal 4ACD , Michel Galinier 1ACD , Oksana Kunduzova 4ACD , Rania Azar 2ACD , Jerome Roncalli 14ABCDEFG*

DOI: 10.12659/MSM.934804

Med Sci Monit 2022; 28:e934804

Table 3 Characteristics of heart failure with preserved ejection fraction (HFpEF) group stratified by the presence of coronary artery disease.

HFpEF populationN=89No CADN=39Significant CADN=50P-value
Age72.53±9.72270.59±10.4374.04±8.950.097
Male sex63 (70.78%)21 (53.85%)42 (84.00%)0.002
BMI27.65±6.5627.99±7.6627.39±5.630.668
Atrial fibrillation25 (28.09%)14 (35.89%)11 (22.00%)0.148
Chronic kidney disease45 (50.56%)18 (46.15%)27 (54.00%)0.538
Dyslipidemia39 (43.82%)14 (35.89%)25 (50.00%)0.237
Diabetes mellitus29 (32.58%)10 (25.64%)19 (38.00%)0.267
Hypertension61 (68.54%)25 (61.10%)36 (72.00%)0.596
Smoking11 (12.36%)3 (7.69%)8 (16.00%)0.338
Family history11 (15.53%)4 (10.25%)7 (14.00%)0.751
Valvopathy29 (32.58%)12 (30.77%)17 (34.00%)0.697
Right ventricular dysfunction6 (6.74%)3 (7.69%)3 (6.00%)0.182
TAPSE16.45±3.4812.67±2.3117.88±2.700.016
PAPSE40.62±10.2641.43±10.2939.67±11.110.772
Pacemaker6 (6.74%)06 (12.00%)0.033
Defibrillator1 (1.12%)01 (2.00%)1
NYHA class
 10.115
 217 (19.10%)4 (10.26%)13 (26.00%)
 320 (22.47%)6 (15.38%)14 (28.00%)
 44 (4.49%)3 (7.69%)1 (2.00%)
Systolic blood pressure137.72±22.43134.52±24.00139.73±21.450.367
Diastolic blood pressure72.92±20.5671.48±29.3173.83±12.760.658
Heart rate77.91±17.9583.48±14.3974.43±19.210.047
Troponin112.13±212.21184.82±344.3672.15±62.860.307
NT-ProBNP4073.81±7245.544523.32±7943.453724.19±6747.790.665
β-blockers41 (46.07%)17 (43.59%)24 (48.00%)0.679
Diuretics50 (56.18%)21 (53.85%)29 (58.00%)0.695
Mineralocorticoids11 (12.36%)4 (10.26%)7 (14.00%)0.749
ACE/ARA51 (57.30%)24 (61.54%)27 (54.00%)0.476
ARNI3 (3.37%)3 (7.69%)00.080
SAPT36 (40.45%)11 (28.21%)25 (50.00%)0.031
DAPT8 (8.98%)1 (2.56%)7 (14.00%)0.075
DOAC+AVK27 (30.34%)11 (28.21%)16 (32.00%)0.699
AAP+OAC6 (6.74%)1 (2.56%)5 (10.00%)0.225
β-blockers58 (65.17%)26 (66.66%)32 (64.00%)0.894
Diuretics62 (69.66%)25 (64.10%)37 (74.00%)0.314
Mineralocorticoids19 (21.35%)9 (23.07%)10 (20.00%)0.725
ACE/ARA65 (73.03%)28 (71.79%)37 (74.00%)0.816
ARNI4 (4.49%)3 (7.69%)1 (2.00%))0.315
Ivabradine2 (2.23%)1 (2.56%)1 (2.00%)1
SAPT33 (37.08%)11 (28.21%)22 (44.00%)0.126
DAPT29 (32.58%)2 (5.13%)27 (54.00%)
DOAC+AVK31 (37.87%)16 (34.83%)15 (38.43%)0.279
AAP+OAC11 (14.31%)2 (12.36%)9 (14.67%)0.103
BMI – body mass index; APT – single anti-platelet therapy; DAPT – dual anti-platelet therapy; DOAC – direct oral anti-coagulant; AP+OAC – anti-platelet +oral anti-coagulant.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor Basic Research eISSN: 2325-4416
Medical Science Monitor Basic Research eISSN: 2325-4416